Dissemin is shutting down on January 1st, 2025

Published in

BioMed Central, Journal of Hematology and Oncology, 1(7), 2014

DOI: 10.1186/s13045-014-0079-z

Links

Tools

Export citation

Search in Google Scholar

Potential therapeutic role of antagomiR17 for the treatment of chronic lymphocytic leukemia

Journal article published in 2014 by Sara Dereani, Paolo Macor ORCID, Tiziana D. Agaro, T. D'Agaro, Tiziana D’Agaro, Nelly Mezzaroba, Michele Dal-Bo, Sara Capolla, Antonella Zucchetto, Erika Tissino, Giovanni Zorzet S. Del Poeta, Sonia Zorzet, Valter Gattei, Riccardo Bomben
This paper is made freely available by the publisher.
This paper is made freely available by the publisher.

Full text: Download

Green circle
Preprint: archiving allowed
Upload
Green circle
Postprint: archiving allowed
Upload
Green circle
Published version: archiving allowed
Upload
Policy details
Data provided by SHERPA/RoMEO

Abstract

Abstract Recently it was reported that microRNA from the miR-17 ~ 92 family may have a key role in chronic lymphocytic leukemia (CLL). Here, we designed specific oligonucleotides to target endogenous miR-17 (antagomiR17). In-vitro administration of antagomiR17 effectively reduced miR-17 expression and the proliferation of CLL-like MEC-1 cells. When injected in-vivo in tumor generated by the MEC-1 cells in SCID mice, antagomiR17 dramatically reduced tumor growth and significantly increase survival. Altogether, our results provide the rationale for the use of antagomiR17 as a novel potential therapeutic tool in CLL and in other lymphoproliferative disorders where miR-17 has a driver role in tumor progression.